thalidomide has been researched along with Aura in 6 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The possibility of epilepsy resulting from maternal thalidomide ingestion was investigated by obtaining a telephoned neurological history from all suspect families in the United Kingdom in which the specific diagnosis was uncertain." | 7.65 | Epilepsy: a neurological complication of thalidomide embryopathy. ( Stephenson, JB, 1976) |
| "The possibility of epilepsy resulting from maternal thalidomide ingestion was investigated by obtaining a telephoned neurological history from all suspect families in the United Kingdom in which the specific diagnosis was uncertain." | 3.65 | Epilepsy: a neurological complication of thalidomide embryopathy. ( Stephenson, JB, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hao, Y | 1 |
| Ou, Y | 1 |
| Zhang, C | 1 |
| Chen, H | 1 |
| Yue, H | 1 |
| Yang, Z | 1 |
| Zhong, X | 1 |
| Hu, W | 1 |
| Sun, P | 1 |
| Palencia, G | 1 |
| Martinez-Juarez, IE | 1 |
| Calderon, A | 1 |
| Artigas, C | 1 |
| Sotelo, J | 1 |
| Stephenson, JB | 1 |
| Kanno, O | 1 |
| Newman, CG | 1 |
| Shiono, H | 1 |
1 review available for thalidomide and Aura
| Article | Year |
|---|---|
[Diseases and dermatoglyphics].
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Bone and Bones; Chromosome Aberrations; Chromo | 1970 |
1 trial available for thalidomide and Aura
| Article | Year |
|---|---|
Thalidomide for treatment of refractory epilepsy.
Topics: Analysis of Variance; Epilepsy; Follow-Up Studies; Humans; Immunosuppressive Agents; Statistics, Non | 2010 |
4 other studies available for thalidomide and Aura
| Article | Year |
|---|---|
Seratrodast, a thromboxane A2 receptor antagonist, inhibits neuronal ferroptosis by promoting GPX4 expression and suppressing JNK phosphorylation.
Topics: Animals; Benzoquinones; Epilepsy; Ferroptosis; Glutathione; Heptanoic Acids; Mice; Pentylenetetrazol | 2022 |
Epilepsy: a neurological complication of thalidomide embryopathy.
Topics: Adolescent; Ear; Electroencephalography; Epilepsy; Epilepsy, Temporal Lobe; Female; Heart Defects, C | 1976 |
Electroencephalographic study of 137 patients with thalidomide embryopathy.
Topics: Adolescent; Adult; Brain; Child; Electroencephalography; Epilepsy; Female; Fetal Diseases; Hearing D | 1987 |
Teratogen update: clinical aspects of thalidomide embryopathy--a continuing preoccupation.
Topics: Abdomen; Abnormalities, Multiple; Cardiovascular Abnormalities; Cranial Nerves; Dentition; Embryo, M | 1985 |